...
首页> 外文期刊>International Journal of Nanomedicine >Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
【24h】

Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology

机译:使用纳米技术将基于miRNA的药物靶向囊性纤维化气道上皮细胞

获取原文
           

摘要

Abstract: Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m)RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenotype. Modulation of miRNA by replacement using miRNA mimics (premiRs) presents a new therapeutic paradigm for CF, but effective and safe methods of delivery to the CF epithelium are limiting clinical translation. Herein, polymeric nanoparticles are investigated for delivery of miRNA mimics into CF airway epithelial cells, using miR-126 as a proof-of-concept premiR cargo to determine efficiency. Two polymers, polyethyleneimine (PEI) and chitosan, were used to prepare miRNA nanomedicines, characterized for their size, surface (zeta) potential, and RNA complexation efficiency, and screened for delivery and cytotoxicity in CFBE41o- (human F508del cystic fibrosis transmembrane conductance regulator bronchial epithelial) cells using a novel high content analysis method. RNA extraction was carried out 24 hours post transfection, and miR-126 and TOM1 (target of Myb1) expression (a validated miR-126 target) was assessed. Manufacture was optimized to produce small nanoparticles that effectively complexed miRNA. Using high content analysis, PEI-based nanoparticles were more effective than chitosan-based nanoparticles in facilitating uptake of miRNA into CFBE41o- cells and this was confirmed in miR-126 assays. PEI-premiR-126 nanoparticles at low nitrogen/phosphate (N/P) ratios resulted in significant knockdown of TOM1 in CFBE41o- cells, with the most significant reduction of 66% in TOM1 expression elicited at an N/P ratio of 1:1 while chitosan-based miR-126 nanomedicines failed to facilitate statistically significant knockdown of TOM1 and both nanoparticles appeared relatively nontoxic. miRNA nanomedicine uptake can be qualitatively and quantitatively assessed rapidly by high content analysis and is highly polymer-dependent but, interestingly, there is not a direct correlation between the levels of miRNA uptake and the downstream gene knockdown. Polymeric nanoparticles can deliver premiRs effectively to CFBEs in order to modulate gene expression but must be tailored specifically for miRNA delivery.
机译:摘要:囊性纤维化(CF)是一种以慢性气道炎症为特征的遗传性疾病。 microRNA(miRNA)是内源性小RNA,在转录后水平上作用于信使(m)RNA,并且人们逐渐认识到,改变的miRNA表达与CF表型有关。通过使用miRNA模拟物(premiRs)替代来调节miRNA提出了CF的新治疗范例,但是有效安全的递送至CF上皮的方法限制了临床翻译。本文中,使用miR-126作为概念验证的premiR货物来确定聚合效率,研究了聚合纳米颗粒用于将miRNA模拟物递送至CF气道上皮细胞。两种聚合物聚乙烯亚胺(PEI)和壳聚糖用于制备miRNA纳米药物,表征其大小,表面(zeta)电位和RNA络合效率,并筛选CFBE41o-(人F508del囊性纤维化跨膜电导调节剂)的递送和细胞毒性支气管上皮细胞)使用一种新颖的高含量分析方法。转染后24小时进行RNA提取,评估miR-126和TOM1(Myb1的靶标)表达(经过验证的miR-126靶标)。优化生产以生产可有效复合miRNA的小纳米颗粒。使用高含量分析,基于PEI的纳米颗粒比基于壳聚糖的纳米颗粒在促进miRNA进入CFBE41o-细胞吸收方面更有效,这在miR-126分析中得到了证实。低氮/磷酸盐(N / P)比的PEI-premiR-126纳米颗粒导致CFBE41o-细胞中TOM1的显着敲低,N / P比率为1:1导致TOM1表达最显着降低66%而基于壳聚糖的miR-126纳米药物未能促进TOM1的统计学显着降低,并且两种纳米颗粒均显示相对无毒。可以通过高含量分析快速定性和定量评估miRNA纳米药物的摄取,并且高度依赖于聚合物,但是有趣的是,miRNA摄取的水平与下游基因敲低之间没有直接关联。聚合纳米颗粒可以有效地将premiRs传递至CFBE,以调节基因表达,但必须专门针对miRNA传递进行定制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号